triazoles has been researched along with rg7388 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blotner, S; Chen, LC; Ejadi, S; Miller, W; Nemunaitis, J; Nichols, G; Razak, A; Vazvaei, F; Young, A; Zhi, J | 1 |
Estey, EH; Percival, MM | 1 |
1 review(s) available for triazoles and rg7388
Article | Year |
---|---|
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
1 other study(ies) available for triazoles and rg7388
Article | Year |
---|---|
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Topics: Administration, Oral; Area Under Curve; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Compounding; Drug Interactions; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tablets; Therapeutic Equivalency; Triazoles | 2018 |